Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mitomycin C reused: an in vitro cost-effectiveness study.

P R Carroll, R D Williams, M J Kim

    The Journal of Urology
    |September 1, 1984
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Search for Gluino-Mediated Bottom Squark Production in pp[over ] Collisions at sqrt[s]=1.96 TeV.

    Physical review letters·2009
    Same author

    Search for exclusive Z-boson production and observation of high-mass pp[over ]-->pgammagammap[over ]-->pl;{+}l;{-}p[over ] events in pp[over ] collisions at sqrt[s]=1.96 TeV.

    Physical review letters·2009
    Same author

    First measurement of the tt[over ] differential cross section dsigma/dM_{tt[over ]} in pp[over ] collisions at sqrt[s]=1.96 TeV.

    Physical review letters·2009
    Same author

    Measurement of the k(T) distribution of particles in jets produced in pp collisions at sqrt(s)=1.96 TeV.

    Physical review letters·2009
    Same author

    Observation of exclusive charmonium production and gammagamma --> micro;{+}micro;{-} in pp[over] collisions at sqrt[s] = 1.96 TeV.

    Physical review letters·2009
    Same author

    Evidence for a narrow near-threshold structure in the J/psivarphi mass spectrum in B;{+} --> J/psivarphiK;{+} decays.

    Physical review letters·2009

    This study shows that mitomycin C, used for bladder cancer, can be recovered and reused for up to two weeks. This reuse of mitomycin C could significantly lower treatment costs for patients.

    Area of Science:

    • Oncology
    • Urology
    • Pharmacology

    Background:

    • Superficial bladder cancer treatment often involves mitomycin C.
    • The high cost of mitomycin C limits its widespread use.
    • Investigating cost-reduction strategies for mitomycin C is crucial.

    Purpose of the Study:

    • To assess the feasibility of recovering and reusing mitomycin C after intravesical administration.
    • To determine the stability and efficacy of recovered mitomycin C over time.
    • To evaluate the potential for cost savings in bladder cancer treatment.

    Main Methods:

    • In vitro study using human transitional carcinoma cell line 253-J.
    • Exposure of cells to fresh, stored, and recovered mitomycin C.
    • Assessment of cell viability via cell counts at 2 and 5 days post-exposure.

    Related Experiment Videos

    Main Results:

    • Fresh and stored mitomycin C (up to 4 weeks) inhibited cell growth to <1% of control.
    • Recovered mitomycin C retained efficacy for up to 2 weeks, with cell growth at 3.1-9.7% of control.
    • Efficacy decreased after 3 weeks of storage, indicating potential loss of potency.

    Conclusions:

    • Mitomycin C can be recovered, stored, and reused for at least two weeks post-administration.
    • Reuse of mitomycin C offers a potential strategy to reduce treatment costs for superficial bladder cancer.
    • Further clinical studies are warranted to confirm the efficacy and safety of reused mitomycin C.